On #CancerSurvivorsDay, we celebrate our patients who have beaten #cancer. Our staff has this message for you!

Congratulations to Robert Andtbacka for leading/presenting the neoadjuvant T-VEC study. cancernetwork.com/news/t-vec-imm…

Prof Omid Hamid MD the southern #California ROCKSTAR #Immunotherapist “You always hurt the one you love” - need to optimize Ipi dose #Bridge18

Dr. Omid Hamid Omid Hamid MD is examining the IL-6 Receptor Inhibitor #Tocilizumab with #Ipilimumab & #Nivolumab to treat unresectable Stage 3 or 4 #Melanoma in a phase 2 study. @AngelesClinic #CedarsSinai #CedarsSinaiCancer #melanomaawarenessmonth cancertrialinfo.csmc.edu/adultcancerspr…

Wanted to notify all of Twitter that I am seeing patients @theangelesclinic direct 310-231-2164 - email [email protected] #melanoma #melasm #immunotherapy #SurgOnc #ImmunoOnc #immunooncology #PD1 #clinicaltrials

Just published (finally!) the Canvaxin trial in Stage IV melanoma. A testament to Don Morton's tenacity. ncbi.nlm.nih.gov/pubmed/29019177

Nice work! Jason Luke, MD, FACP giving great talk on what's next in immunotherapy. #worldmelanomacongress

John Wayne alumni fellow Vern Sondak co - chairing plenary session at # worldcongressofmelanoma

Great doctor and great person, Dr. Ann Partridge ( @YoungStrongDFCI ) featured in ASCO post. Great job Ann!

Sunrise over LA. Heading to Stanford for Eye Am Not Alone conference. #ocularmelanoma Looks like a great meeting.

Prof Nicola Mozzillo melanoma surgeon extraordinaire receives award from Dr Paolo A. Ascierto for decades of leadership and advancing treatments to #FINISHCANCER / Dr Mozzillo’s address remembers Dr Don Morton @JohnWayneCI & @Prov_Health #Bridge2017 Fondazione Melanoma thanks MarkFariesMD

.Jeffrey Gershenwald MarkFariesMD & colleagues review the evidence-based changes in the AJCC 8th edition #Melanoma staging guidelines onlinelibrary.wiley.com/doi/10.3322/ca…